Company Filing History:
Years Active: 2018-2021
Title: Fumin Chang: Innovator in Cardiovascular Treatment
Introduction
Fumin Chang is a notable inventor based in Baltimore, MD (US). He has made significant contributions to the field of cardiovascular medicine through his innovative research and patented technologies. With a total of 2 patents, Chang's work focuses on the development of antibodies that target specific proteins involved in cardiovascular disorders.
Latest Patents
Chang's latest patents include groundbreaking work on antibodies specific for LOX1, a protein implicated in various cardiovascular conditions. This disclosure provides LOX1 binding proteins, such as anti-LOX1 antibodies, along with compositions and methods for their production. These LOX1-binding proteins are designed to inhibit or antagonize LOX1 activity. Furthermore, the patents outline methods for diagnosing and treating conditions associated with atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia, myocardial infarction, acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, chronic inflammation, angiogenesis, preeclampsia, cancer, and other LOX1-mediated diseases and conditions.
Career Highlights
Fumin Chang is currently associated with MedImmune Limited, where he continues to advance his research in the field of immunology and cardiovascular health. His work has the potential to significantly impact the treatment of various cardiovascular diseases, improving patient outcomes and quality of life.
Collaborations
Chang has collaborated with notable colleagues, including Andrew Grier Buchanan and Matthieu Chodorge. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to the development of effective therapeutic solutions.
Conclusion
Fumin Chang's contributions to the field of cardiovascular treatment through his patented innovations highlight the importance of research and collaboration in advancing medical science. His work continues to pave the way for new therapies that address critical health challenges.